{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:07:32Z","timestamp":1789873652662,"version":"4.0.1"},"reference-count":36,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent clinical trials in both transplant-eligible and -ineligible newly diagnosed multiple myeloma using 3- and 4-drug combinations have demonstrated unprecedented levels of response. However, 2 recently published studies redefining high risk in newly diagnosed multiple myeloma in the context of these newer and more effective treatments demonstrate that a significant minority of patients likely derive little benefit from these newer approaches. These new prognostic systems thus provide an evidence-based framework for the development of much-needed risk-stratified clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024023841","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:14:57Z","timestamp":1753906497000},"page":"1546-1549","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["New prognostic systems for multiple myeloma in the context of contemporary therapies"],"prefix":"10.1182","volume":"146","author":[{"given":"Andrew","family":"Spencer","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology, Alfred Health-Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"15","key":"2025092511211829600_bib1","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"2025092511211829600_bib2","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from the International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"29","key":"2025092511211829600_bib3","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) within the HARMONY project","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025092511211829600_bib4","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/bjh.18536","article-title":"The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: real world data results in an Australian and New Zealand population","volume":"200","author":"Tan","year":"2023","journal-title":"Br J Haematol"},{"issue":"14","key":"2025092511211829600_bib5","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1097\/CM9.0000000000002735","article-title":"Prognostic value of the second revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma","volume":"136","author":"Yan","year":"2023","journal-title":"Chin Med J"},{"issue":"5","key":"2025092511211829600_bib6","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/bjh.19384","article-title":"Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation","volume":"204","author":"Alzahrani","year":"2024","journal-title":"Br J Haematol"},{"issue":"24","key":"2025092511211829600_bib7","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1200\/JCO-24-01253","article-title":"Co-occurrence of cytogenetic abnormalities and high-risk disease in newly diagnosed and relapsed\/refractory multiple myeloma","volume":"43","author":"Kaiser","year":"2025","journal-title":"J Clin Oncol"},{"issue":"24","key":"2025092511211829600_bib8","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025092511211829600_bib9","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/sj.leu.2404832","article-title":"Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials","volume":"21","author":"Moreau","year":"2007","journal-title":"Leukemia"},{"issue":"13","key":"2025092511211829600_bib10","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood-2014-07-587964","article-title":"Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience","volume":"125","author":"Hebraud","year":"2015","journal-title":"Blood"},{"issue":"19","key":"2025092511211829600_bib11","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025092511211829600_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/bmt.2009.107","article-title":"1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"45","author":"Chang","year":"2010","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"2025092511211829600_bib13","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.2022017863","article-title":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor","volume":"141","author":"Schavgoulidze","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2025092511211829600_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"2025092511211829600_bib15","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2019001425","article-title":"Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents","volume":"4","author":"Giri","year":"2020","journal-title":"Blood Adv"},{"issue":"15","key":"2025092511211829600_bib16","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","article-title":"Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities","volume":"4","author":"Abdallah","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2025092511211829600_bib17","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"issue":"23","key":"2025092511211829600_bib18","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2018-06-857250","article-title":"Subclonal TP53 copy number is associated with prognosis in multiple myeloma","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025092511211829600_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"2025092511211829600_bib20","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2025092511211829600_bib21","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2025092511211829600_bib22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3390\/cancers11070917","article-title":"DNA-repair gene mutations are highly prevalent in circulating tumour DNA from multiple myeloma patients","volume":"11","author":"Mithraprabhu","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"2025092511211829600_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: Pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025092511211829600_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-019-0191-y","article-title":"Natural history of multiple myeloma with de novo del(17p)","volume":"9","author":"Lakshman","year":"2019","journal-title":"Blood Cancer J"},{"issue":"20","key":"2025092511211829600_bib25","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.3390\/cancers14205169","article-title":"NGS-based molecular karyotyping of multiple myeloma: Results from the GEM12 clinical trial","volume":"14","author":"Rosa-Rosa","year":"2022","journal-title":"Cancers"},{"issue":"24","key":"2025092511211829600_bib26","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-20-2283","article-title":"Implications of MYC rearrangements in newly diagnosed multiple myeloma","volume":"26","author":"Abdallah","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025092511211829600_bib27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2025092511211829600_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-023-00796-9","article-title":"Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma","volume":"13","author":"Mithraprabhu","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025092511211829600_bib29","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/ejh.14296","article-title":"MYC translocation is a valuable marker for the development and relapse of extramedullary disease in multiple myeloma","volume":"113","author":"Song","year":"2024","journal-title":"Eur J Haematol"},{"issue":"9","key":"2025092511211829600_bib30","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","article-title":"Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2025092511211829600_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-020-00948-5","article-title":"Daratumumab, bortezomib and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk","volume":"13","author":"Weisel","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2025092511211829600_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/bjh.17499","article-title":"Subgroup analysis of ICARIA-MM study in relapsed\/refractory multiple myeloma patients with high-risk cytogenetics","volume":"194","author":"Harrison","year":"2021","journal-title":"Br J Haematol"},{"issue":"23","key":"2025092511211829600_bib33","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"2025092511211829600_bib34","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood-2015-05-644039","article-title":"Prediction of high- and low-risk multiple myeloma based on gene expression and the international staging system","volume":"126","author":"Kuiper","year":"2015","journal-title":"Blood"},{"issue":"17","key":"2025092511211829600_bib35","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2025092511211829600_bib36","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/13\/1546\/2413083\/blood_bld-2024-023841-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/13\/1546\/2413083\/blood_bld-2024-023841-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:21:27Z","timestamp":1758813687000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/13\/1546\/546413\/New-prognostic-systems-for-multiple-myeloma-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":36,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024023841","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,25]]},"published":{"date-parts":[[2025,9,25]]}}}